{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:21:00Z","timestamp":1789597260005,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The choice of an efficient psychotropic treatment for patients with schizophrenia is a key issue to improve prognosis and quality of life and to decrease the related burden and costs. As for other complex disorders, response to drugs in schizophrenia is highly heterogeneous and the underlying molecular mechanisms of this diversity are still poorly understood. In a carefully followed-up cohort of schizophrenic patients prospectively treated with risperidone or olanzapine, we used a specially designed single-nucleotide polymorphism (SNP) array to perform a large-scale genomic analysis and identify genetic variants associated with response to psychotropic drugs. We found significant associations between response to treatment defined by the reduction in psychotic symptomatology 42 days after the beginning of treatment and SNPs located in the chromosome 6, which houses the human leukocyte antigen (HLA). After imputation of the conventional <jats:italic>HLA<\/jats:italic> class I and class II alleles, as well as the amino-acid variants, we observed a striking association between a better response to treatment and a double amino-acid variant at positions 62 and 66 of the peptide-binding groove of the HLA-A molecule. These results support the current notion that schizophrenia may have immune-inflammatory underpinnings and may contribute to pave the way for personalized treatments in schizophrenia.<\/jats:p>","DOI":"10.1038\/tp.2015.97","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T13:42:11Z","timestamp":1438090931000},"page":"e608-e608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia"],"prefix":"10.1038","volume":"5","author":[{"given":"S","family":"Le Clerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Taing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Fond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Meary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P-M","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Beaune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jamain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tamouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-F","family":"Zagury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Leboyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,28]]},"reference":[{"key":"BFtp201597_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s004060070002","volume":"250","author":"A Jablensky","year":"2000","unstructured":"Jablensky A . Epidemiology of schizophrenia: t he global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250: 274\u2013285.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFtp201597_CR2","unstructured":"Schizophrenia Commission The Abandoned Illness: a Report by the Schizophrenia Commission. Rethink Mental Illness: London, UK, 2012."},{"key":"BFtp201597_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1017\/S2045796013000097","volume":"23","author":"D King","year":"2014","unstructured":"King D, Knapp M, Patel A, Amaddeo F, Tansella M, Schene A et al. The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study. Epidemiol Psychiatr Sci 2014; 23: 61\u201370.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"BFtp201597_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/schbul\/sbv002","volume":"41","author":"G Fond","year":"2015","unstructured":"Fond G, d'Albis MA, Jamain S, Tamouza R, Arango C, Fleischhacker WW et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull 2015; 41: 559\u2013573.","journal-title":"Schizophr Bull"},{"key":"BFtp201597_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/14622416.10.3.385","volume":"10","author":"M Gupta","year":"2009","unstructured":"Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009; 10: 385\u2013397.","journal-title":"Pharmacogenomics"},{"key":"BFtp201597_CR6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2217\/pgs.14.50","volume":"15","author":"MD Brennan","year":"2014","unstructured":"Brennan MD . Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 2014; 15: 869\u2013884.","journal-title":"Pharmacogenomics"},{"key":"BFtp201597_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2009.89","volume":"16","author":"JL McClay","year":"2011","unstructured":"McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16: 76\u201385.","journal-title":"Mol Psychiatry"},{"key":"BFtp201597_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.biopsych.2009.08.030","volume":"67","author":"M Ikeda","year":"2010","unstructured":"Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67: 263\u2013269.","journal-title":"Biol Psychiatry"},{"key":"BFtp201597_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics C","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511: 421\u2013427.","journal-title":"Nature"},{"key":"BFtp201597_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nature08192","volume":"460","author":"J Shi","year":"2009","unstructured":"Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753\u2013757.","journal-title":"Nature"},{"key":"BFtp201597_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/acps.12211","volume":"129","author":"G Fond","year":"2014","unstructured":"Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 2014; 129: 163\u2013179.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtp201597_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/archpsyc.1994.03950110009002","volume":"51","author":"JI Nurnberger Jr","year":"1994","unstructured":"Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51: 849\u2013859, discussion 863\u2013864.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp201597_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0165-1781(98)00038-9","volume":"79","author":"J Ventura","year":"1998","unstructured":"Ventura J, Liberman RP, Green MF, Shaner A, Mintz J . Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I\/P). Psychiatry Res 1998; 79: 163\u2013173.","journal-title":"Psychiatry Res"},{"key":"BFtp201597_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261\u2013276.","journal-title":"Schizophr Bull"},{"key":"BFtp201597_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1176\/ajp.119.2.164","volume":"119","author":"DR Gorham","year":"1962","unstructured":"Gorham DR, Betz BJ . Characteristics of change of schizophrenic patients during treatment. Am J Psychiatry 1962; 119: 164\u2013167.","journal-title":"Am J Psychiatry"},{"key":"BFtp201597_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"AL Price","year":"2006","unstructured":"Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904\u2013909.","journal-title":"Nat Genet"},{"key":"BFtp201597_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559\u2013575.","journal-title":"Am J Hum Genet"},{"key":"BFtp201597_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"GR Abecasis","year":"2012","unstructured":"1000 Genomes Project Consortium Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56\u201365.","journal-title":"Nature"},{"key":"BFtp201597_CR19","doi-asserted-by":"publisher","first-page":"e64683","DOI":"10.1371\/journal.pone.0064683","volume":"8","author":"X Jia","year":"2013","unstructured":"Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013; 8: e64683.","journal-title":"PLoS One"},{"key":"BFtp201597_CR20","doi-asserted-by":"publisher","first-page":"e39498","DOI":"10.1371\/journal.pone.0039498","volume":"7","author":"S de Jong","year":"2012","unstructured":"de Jong S, Boks MP, Fuller TF, Strengman E, Janson E, de Kovel CG et al. A gene co-expression network in whole blood of schizophrenia patients is independent of antipsychotic-use and enriched for brain-expressed genes. PLoS One 2012; 7: e39498.","journal-title":"PLoS One"},{"key":"BFtp201597_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/0269881113490329","volume":"27","author":"TR Powell","year":"2013","unstructured":"Powell TR, Tansey KE, Breen G, Farmer AE, Craig IW, Uher R et al. ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. J Psychopharmacol 2013; 27: 609\u2013615.","journal-title":"J Psychopharmacol"},{"key":"BFtp201597_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1523\/JNEUROSCI.4109-07.2008","volume":"28","author":"GF Hedou","year":"2008","unstructured":"Hedou GF, Koshibu K, Farinelli M, Kilic E, Gee CE, Kilic U et al. Protein phosphatase 1-dependent bidirectional synaptic plasticity controls ischemic recovery in the adult brain. J Neurosci 2008; 28: 154\u2013162.","journal-title":"J Neurosci"},{"key":"BFtp201597_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2165\/11595380-000000000-00000","volume":"25","author":"MJ Arranz","year":"2011","unstructured":"Arranz MJ, Rivera M, Munro JC . Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011; 25: 933\u2013969.","journal-title":"CNS Drugs"},{"key":"BFtp201597_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.biopsych.2013.10.003","volume":"75","author":"AK McAllister","year":"2014","unstructured":"McAllister AK . Major histocompatibility complex I in brain development and schizophrenia. Biol Psychiatry 2014; 75: 262\u2013268.","journal-title":"Biol Psychiatry"},{"key":"BFtp201597_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0920-9964(00)00105-5","volume":"48","author":"M Marchini","year":"2001","unstructured":"Marchini M, Scorza R, Antonioli R, Scarone S, Grassi B, Epifani M et al. HLA-A2 and B35 are strong predictors of responsiveness to clozapine: preliminary data in Italian schizophrenia patients. Schizophr Res 2001; 48: 363\u2013365.","journal-title":"Schizophr Res"},{"key":"BFtp201597_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1440-1711.1998.00725.x","volume":"76","author":"IB Jakobsen","year":"1998","unstructured":"Jakobsen IB, Gao X, Easteal S, Chelvanayagam G . Correlating sequence variation with HLA-A allelic families: implications for T cell receptor binding specificities. Immunol Cell Biol 1998; 76: 135\u2013142.","journal-title":"Immunol Cell Biol"},{"key":"BFtp201597_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B . Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663\u2013671.","journal-title":"Biol Psychiatry"},{"key":"BFtp201597_CR28","unstructured":"Severance EG, Yolken RH, Eaton WW . Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res 2014; PPI: pii: S0920-9964(14)00319-3."},{"key":"BFtp201597_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.pnpbp.2008.12.006","volume":"33","author":"H Sugino","year":"2009","unstructured":"Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y . Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 303\u2013307.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tp201597.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp201597","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp201597.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:50:42Z","timestamp":1672912242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp201597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,28]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"alternative-id":["BFtp201597"],"URL":"https:\/\/doi.org\/10.1038\/tp.2015.97","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,28]]},"assertion":[{"value":"16 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}